Shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) have received an average recommendation of “Hold” from the twenty-one analysts that are presently covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating, five have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $392.50.
REGN has been the topic of several research analyst reports. Canaccord Genuity reissued a “hold” rating and set a $353.00 target price (down from $408.00) on shares of Regeneron Pharmaceuticals in a research note on Wednesday, May 8th. ValuEngine cut Regeneron Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, June 7th. JPMorgan Chase & Co. reissued a “hold” rating on shares of Regeneron Pharmaceuticals in a research note on Friday, June 21st. Credit Suisse Group reduced their target price on Regeneron Pharmaceuticals from $333.00 to $325.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 7th. Finally, Argus cut Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, June 18th.
Hedge funds have recently modified their holdings of the stock. Altfest L J & Co. Inc. purchased a new stake in Regeneron Pharmaceuticals in the second quarter worth $538,000. Schaper Benz & Wise Investment Counsel Inc. WI boosted its holdings in Regeneron Pharmaceuticals by 1.3% in the first quarter. Schaper Benz & Wise Investment Counsel Inc. WI now owns 16,826 shares of the biopharmaceutical company’s stock worth $6,909,000 after acquiring an additional 216 shares in the last quarter. Oregon Public Employees Retirement Fund boosted its holdings in Regeneron Pharmaceuticals by 47.9% in the first quarter. Oregon Public Employees Retirement Fund now owns 26,027 shares of the biopharmaceutical company’s stock worth $10,687,000 after acquiring an additional 8,434 shares in the last quarter. Kendall Capital Management boosted its holdings in Regeneron Pharmaceuticals by 54.9% in the first quarter. Kendall Capital Management now owns 1,329 shares of the biopharmaceutical company’s stock worth $546,000 after acquiring an additional 471 shares in the last quarter. Finally, Gilman Hill Asset Management LLC bought a new stake in Regeneron Pharmaceuticals in the first quarter worth $205,000. 66.97% of the stock is currently owned by institutional investors.
Shares of REGN traded up $3.74 during mid-day trading on Friday, hitting $296.85. 730,200 shares of the company’s stock traded hands, compared to its average volume of 733,513. The company has a quick ratio of 3.11, a current ratio of 3.88 and a debt-to-equity ratio of 0.07. Regeneron Pharmaceuticals has a 1 year low of $287.66 and a 1 year high of $442.00. The firm has a market capitalization of $32.19 billion, a P/E ratio of 14.99, a PEG ratio of 1.34 and a beta of 1.15. The business’s 50-day moving average price is $304.13 and its 200-day moving average price is $350.53.
Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Tuesday, August 6th. The biopharmaceutical company reported $5.29 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $4.60 by $0.69. Regeneron Pharmaceuticals had a return on equity of 25.79% and a net margin of 28.59%. The firm had revenue of $1.93 billion for the quarter, compared to analysts’ expectations of $1.80 billion. During the same period in the previous year, the firm earned $5.45 earnings per share. The business’s revenue was up 20.3% compared to the same quarter last year. Sell-side analysts anticipate that Regeneron Pharmaceuticals will post 19.22 earnings per share for the current fiscal year.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.